Phase III Insulin Add-On Asia Regional Program - ST

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose is to determine if after 24 weeks of oral daily administration, there will be a greater mean reduction from baseline in glycosylated hemoglobin (HbA1c) achieved with Dapagliflozin 10 mg plus insulin compared to placebo plus insulin in subjects with type 2 diabetes.
Epistemonikos ID: 62bae274c624f40626f1b0da88582cb70714fb98
First added on: May 11, 2024